Fedratinib Hydrochloride and Tafamidis

• Generic Name: fedratinib
• Dosage Forms: n.a.
• Other Brand Names: Inrebic

Fedratinib hydrochloride is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).

• Generic Name: tafamidis
• Dosage Forms: n.a.
• Other Brand Names: Vyndamax, Vyndaqel

Tafamidis affects a protein called transthyretin (TTR, made primarily in the liver). Transthyretin-mediated amyloidosis (ATTR) is a condition in which abnormal deposits of TTR protein build-up in many parts of the body, interfering with normal function. A build-up of TTR in the heart can lead to heart failure.

People with hereditary ATTR amyloidosis have a DNA mutation that can be passed from one generation to the next. People with wild-type ATTR amyloidosis do not have abnormal DNA and cannot pass on the condition.

Tafamidis is used in adults with hereditary or wild type ATTR to treat cardiomyopathy (damage of the heart muscle) caused by a build-up of TTR.

Tafamidis may also be used for purposes not listed in this medication guide.